Abstract: This disclosure relates to a method and reagents for determining ligands in biological fluids such as serum, plasma, spinal fluid, amnionic fluid and urine. This disclosure also relates to a novel class of tracer compounds employed as reagents in fluorescence polarization immunoassays.

Abstract: This disclosure relates to a method for determining ligands in biological fluids such as serum, plasma, spinal fluid, amnionic fluid and urine, wherein a novel class of aminomethylfluorescein derivative tracer compounds are employed as reagents in fluorescence polarization immunoassays.

Abstract: A method for preparing 2-methyl-2-N-formylamino-1-propanol by the step of reacting 2-amino-2-methyl-1-propanol with chloral in about an equimolar ratio at ambient to elevated temperatures.

Abstract: Resorcylic acid lactone compounds of the formula: ##STR1## wherein -A- is either --CH.sub.2 --CH.sub.2 -- or --CH.dbd.CH; >Z is either >CH.sub.2, >C.dbd.0 or >CH-OH; and R and R.sub.1 are either H or a C.sub.3 group selected from propyl and --CH.sub.2 CH.dbd.CH.sub.2, and are different from each other. Such compounds and their derivatives are provided as growth promoting agents for animals, e.g. ruminants and poultry.

Abstract: A compound useful for treating disorders of the heart is disclosed having the formula ##STR1## or pharmaceutically-acceptable salts thereof, wherein x is an integer from 1 to about 10, and R.sub.1 is selected from the group consisting of lower alkyl of from 1 to about 5 carbon atoms.

Abstract: A process for the synthesis of 4,5,6-trihydroxyisophthalic acid by reacting dialkyl glutarate with dialkyl dialkoxymalonate.

Abstract: A method for the production of 2-[(2-hydroxymethyl)phenyl]-2-oxazolines by condensing o-phthalaldehyde with an alkanolamine represented by the formula ##STR1## where R is an alkyl group of 1 to 3 carbon atoms and R.sup.1 is hydrogen or methyl. The compounds have utility as tranquilizing agents.

Abstract: Novel zearalin ethers are disclosed, which are represented by the formula: ##STR1## wherein Y may be a single bond or double bond; A may be --CH.sub.2 --, >C.dbd.O, or >CHOR.sub.1 ; R represents substituents on each of the aromatic rings in either the 2 or 4 positions and may be H or OR.sub.1 ; R.sub.1 may be lower alkyl, lower acyl, monocyclic aryl, or monocyclic aralkyl; R.sub.2 represents a substituent common to each of the aromatic rings at either of the 2 or 4 positions which are not substituted by R, and is represented by the formula --OR.sub.3 O--, wherein R.sub.3 is a straight chain or branched chain hydrocarbon; and each aromatic ring may be unsubstituted in the 3 and 5 positions or may be further substituted with one or more halo substituents. Also discosed are methods for making the above compounds, and animal feeds containing such compounds.

Abstract: Novel steroid ethers are disclosed, which are represented by the formula: ##STR1## wherein Z is selected from the group consisting of >C=O >CHOH, and ##STR2## X is selected from the group consisting of --H and --OH, and R is selected from the group consisting of ##STR3## wherein R.sub.1 is a straight or branched chain hydrocarbon of from 1 to about 16 carbon atoms; A is selected from the group consisting of --CH.sub.2 --, >C=O, and >CHOR.sub.3 ; Y may be a single bond or a double bond; R.sub.2 and --R.sub.1 O-- represent substituents on the aromatic ring of the group of the second formula, in either the 2 or 4 positions, and R.sub.2 is selected from the group consisting of H and OR.sub.3 ; R.sub.

Abstract: A process for the synthesis of pyrogallol from glutaric ester and dialkoxymalonic ester.

Abstract: Reduced bacitracin and pharmaceutically acceptable salts thereof obtained by treating bacitracin with a reducing agent. The resulting product has improved stability.